Skip to content

Meg J. Spriggs

21 papers in the library · 704 citations · publishing 2017-2026

Papers

Sort Most recent Most cited

Psilocybin therapy for adult females with anorexia nervosa: pilot study.

The British Journal of Psychiatry July 8, 2026 Hannah Douglass, Meg J. Spriggs, Kate Godfrey et al.

Background Anorexia nervosa is a debilitating eating disorder with high mortality and chronicity rates owing to the paucity of effective existing treatments. Several clinical trials using psilocybin therapy have demonstrated therapeutic efficacy and safety in psychiatric conditions, including anorexia nervosa. Aims This study aimed to further assess the safety, feasibility and potential...

Enhanced meaning in life following psychedelic use: converging evidence from controlled and naturalistic studies

Frontiers in Psychology June 6, 2025 William Roseby, Hannes Kettner, Leor Roseman et al. 6 citations

Introduction Psychedelics, such as psilocybin, are increasingly recognized for their propensity to elicit powerful subjective experiences that carry personal meaning. While research has demonstrated the capacity for these compounds to promote psychological wellbeing, it has yet to be shown to what extent they modulate "meaning in life", a specific contributor to mental and physical health....

DOI: 10.3389/fpsyg.2025.1580663 (opens in new tab) Naturalism Meaning existential Cognitive psychology Psychotherapist +3

From relaxed beliefs under psychedelics (REBUS) to revised beliefs after psychedelics (REBAS).

Scientific Reports January 29, 2025 Richard J. Zeifman, Meg J. Spriggs, Hannes Kettner et al. 26 citations

The Relaxed Beliefs Under pSychedelics (REBUS) model proposes that serotonergic psychedelics decrease the precision weighting of neurobiologically-encoded beliefs. We conducted a preliminary examination of two psychological assumptions of REBUS: (a) psychedelics foster acute relaxation and post-acute revision of confidence in mental-health-relevant beliefs; which (b) facilitate positive...

DOI: 10.1038/s41598-023-28111-3 (opens in new tab) Full text (opens in new tab) Psilocybin therapy Cognitive flexibility Psychedelics Mental health

An investigation of acute physiological and psychological moderators of psychedelic-induced personality change among healthy volunteers

Neuroscience Applied December 2, 2024 Kate Godfrey, Brandon Weiss, Joseph Peill et al. 5 citations

This study investigated the effects of a single high-dose of psilocybin on personality traits in psychedelic-naïve healthy volunteers. These data originate from a larger within-subjects fixed-order design trial, where a single high dose of psilocybin (25 mg) was administered in a psychologically supportive setting and was compared against a (one-month) prior, 1 mg 'placebo' dose. Personality...

DOI: 10.1016/j.nsa.2024.104092 (opens in new tab) Personality Clinical psychology

Neuroplasticity and Psychedelics: a comprehensive examination of classic and non-classic compounds in pre and clinical models

arXiv Preprint Archive November 29, 2024 Claudio Agnorelli, Meg J. Spriggs, Kate Godfrey et al. 32 citations preprint

Neuroplasticity, the ability of the nervous system to adapt throughout an organism's lifespan, offers potential as both a biomarker and treatment target for neuropsychiatric conditions. Psychedelics, a burgeoning category of drugs, are increasingly prominent in psychiatric research, prompting inquiries into their mechanisms of action. Distinguishing themselves from traditional medications,...

Full text (opens in new tab) Neuroplasticity Q-bio.nc Q-bio.bm Psychopharmacology +1

Beyond the numbers: reimagining healing with psychedelics for eating disorders.

Journal of Eating Disorders September 30, 2024 Adele Lafrance, Meg J. Spriggs, Natalie Gukasyan et al. 8 citations

Psychedelic medicine is currently being evaluated for numerous mental health indications, and there is significant interest in applying these models of care to eating disorders (EDs) given the limited efficacy of available treatment models, especially for those living with anorexia nervosa. Preliminary findings across a number of studies suggest promise. In this commentary, researchers with...

DOI: 10.1186/s40337-024-01111-y (opens in new tab) Full text (opens in new tab) Psychedelic therapy Mental health treatment Psilocybin research Anorexia nervosa +3

Effects of discontinuation of serotonergic antidepressants prior to psilocybin therapy versus escitalopram for major depression

Journal of Psychopharmacology March 22, 2024 Tommaso Barba, David Erritzøe, Meg J. Spriggs et al. 26 citations

Background: There is growing evidence for the therapeutic effects of the psychedelic drug psilocybin for major depression. However, due to the lack of safety data on combining psilocybin with selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) and concerns that there may be a negative interaction on efficacy, participants enrolling in...

When the Trial Ends: The Case for Post-Trial Provisions in Clinical Psychedelic Research

Neuroethics November 6, 2023 Edward Jacobs, Ashleigh Murphy-Beiner, Ian Rouiller et al. 23 citations

Abstract The ethical value—and to some scholars, necessity—of providing trial patients with post-trial access (PTA) to an investigational drug has been subject to significant attention in the field of research ethics. Although no consensus has emerged, it seems clear that, in some trial contexts, various factors make PTA particularly appropriate. We outline the atypical aspects of psychedelic...

DOI: 10.1007/s12152-023-09536-z (opens in new tab) Full text (opens in new tab) Clinical trial Declaration of helsinki Bureaucracy Informed consent +1

ARC: a framework for access, reciprocity and conduct in psychedelic therapies

Frontiers in Psychology May 11, 2023 Hannah Thurgur, Meg J. Spriggs, Ashleigh Murphy-Beiner et al. 13 citations

The field of psychedelic assisted therapy (PAT) is growing at an unprecedented pace. The immense pressures this places on those working in this burgeoning field have already begun to raise important questions about risk and responsibility. It is imperative that the development of an ethical and equitable infrastructure for psychedelic care is prioritized to support this rapid expansion of PAT...

DOI: 10.3389/fpsyg.2023.1119115 (opens in new tab) Reciprocity cultural anthropology Stakeholder Public relations Mental health +1

Body mass index (BMI) does not predict responses to psilocybin

Journal of Psychopharmacology November 14, 2022 Meg J. Spriggs, Bruna Giribaldi, Taylor Lyons et al. 15 citations

Background: Psilocybin is a serotonin type 2A (5-HT 2A ) receptor agonist and naturally occurring psychedelic. 5-HT 2A receptor density is known to be associated with body mass index (BMI), however, the impact of this on psilocybin therapy has not been explored. While body weight-adjusted dosing is widely used, this imposes a practical and financial strain on the scalability of psychedelic...

A Bayesian Reanalysis of a Trial of Psilocybin Versus Escitalopram for Depression

Psychedelic Medicine October 28, 2022 Bruna Giribaldi, Sandeep M. Nayak, Bilal A. Bari et al. 15 citations

Background: A trial of psilocybin (COMP360) versus escitalopram for major depressive disorder (MDD) was reported as negative, as there was no significant difference in the primary outcome, mean change in the 16-item Quick Inventory of Depressive Symptomatology–Self-Report (QIDS SR-16). However, analyses using three other depression scales (17-item Hamilton Depression Rating Scale [HAMD-17],...

Psychedelics therapeutics: What we know, what we think, and what we need to research.

Neuropharmacology September 27, 2022 David Nutt, Meg J. Spriggs, David Erritzøe 77 citations

Psychedelic therapy is perhaps the most exciting new development in psychiatry. Not only does it offer a radical new approach to treatment where mainstream approaches have proven ineffective, but the growing evidence for transdiagnostic efficacy is eliciting a re-think of current diagnostic and symptom-specific approaches to psychiatry. This excitement has led to a massive investment in this...

From Relaxed Beliefs Under Psychedelics (REBUS) to Revised Beliefs After Psychedelics (REBAS): Preliminary Development of the RElaxed Beliefs Questionnaire (REB-Q)

July 7, 2022 Richard J. Zeifman, Meg J. Spriggs, Hannes Kettner et al. 13 citations preprint

Background: The Relaxed Beliefs Under pSychedelics (REBUS) model proposes that serotonergic psychedelics decrease the precision weighting of neurobiologically-encoded beliefs, and offers a unified account of the acute and therapeutic action of psychedelics. Although REBUS has received some neuroscientific support, little research has examined its psychological validity. We conducted a...

Self-Medication for Chronic Pain Using Classic Psychedelics: A Qualitative Investigation to Inform Future Research

Frontiers in Psychiatry November 12, 2021 Julia Bornemann, James B. Close, Meg J. Spriggs et al. 43 citations

Background: Chronic Pain is among the leading causes of disability worldwide with up to 60% of patients suffering from comorbid depression. Psychedelic-assisted therapy has recently been found effective in treating a host of mental health issues including depression and has historically been found to be useful in treating pain. Reports of self-medication for chronic pain using psychedelic drugs...

DOI: 10.3389/fpsyt.2021.735427 (opens in new tab) Mindfulness Chronic pain Cognitive reframing Population +3

Study Protocol for “Psilocybin as a Treatment for Anorexia Nervosa: A Pilot Study”

Frontiers in Psychiatry October 20, 2021 Meg J. Spriggs, Hannah Douglass, Rebecca J. Park et al. 78 citations

Background: Anorexia nervosa (AN) is a serious and life-threatening psychiatric condition. With a paucity of approved treatments, there is a desperate need for novel treatment avenues to be explored. Here, we present (1) an overview of the ways through which Public Patient Involvement (PPI) has informed a trial of psilocybin-assisted therapy for AN and (2) a protocol for a pilot study of...

DOI: 10.3389/fpsyt.2021.735523 (opens in new tab) Psilocybin Anorexia nervosa Protocol science Psychopathology +4

Co-design of Guidance for Patient and Public Involvement in Psychedelic Research

Frontiers in Psychiatry September 30, 2021 James B. Close, Julia Bornemann, Maria Piggin et al. 21 citations

Within the context of scientific research, patient and public involvement (PPI) is defined as research performed “with” or “by” patients and members of the public, rather than “to,” “about”, or “for” them. When carried out systematically and thoughtfully, PPI has the potential to strengthen the quality and impact of research by fostering accountability, transparency, and relevance. There exist...

A qualitative and quantitative account of patient's experiences of ketamine and its antidepressant properties.

Journal of Psychopharmacology August 1, 2021 Rachael Sumner, Emme Chacko, Rebecca McMillan et al. 68 citations

Ketamine is central to one of the most rapidly growing areas of neuroscientific research into novel treatments for depression. Limited research has indicated that the psychedelic properties of ketamine may play a role in its antidepressant effects. The aim of the current study was to explore the psychedelic experiences and sustained impact of ketamine in major depressive disorder. In the...

Positive expectations predict improved mental-health outcomes linked to psychedelic microdosing

Scientific Reports January 21, 2021 Laura Kaertner, Michael B. Steinborn, Hannes Kettner et al. 152 citations

Abstract Psychedelic microdosing describes the ingestion of near-threshold perceptible doses of classic psychedelic substances. Anecdotal reports and observational studies suggest that microdosing may promote positive mood and well-being, but recent placebo-controlled studies failed to find compelling evidence for this. The present study collected web-based mental health and related data using...

Ketamine improves short-term plasticity in depression by enhancing sensitivity to prediction errors.

European Neuropsychopharmacology September 2020 Rachael Sumner, Rebecca McMillan, Meg J. Spriggs et al.

Major depressive disorder negatively impacts the sensitivity and adaptability of the brain's predictive coding framework. The current electroencephalography study into the antidepressant properties of ketamine investigated the downstream effects of ketamine on predictive coding and short-term plasticity in thirty patients with depression using the auditory roving mismatch negativity (rMMN). The...

Ketamine Enhances Visual Sensory Evoked Potential Long-term Potentiation in Patients With Major Depressive Disorder.

Biological Psychiatry: Cognitive Neuroscience and Neuroimaging January 2020 Rachael Sumner, Rebecca McMillan, Meg J. Spriggs et al.

The rapid-acting clinical effects of ketamine as a novel treatment for depression along with its complex pharmacology have made it a growing research area. One of the key mechanistic hypotheses for how ketamine works to alleviate depression is by enhancing long-term potentiation (LTP)-mediated neural plasticity. The objective of this study was to investigate the plasticity hypothesis in 30...

LSD modulates effective connectivity and neural adaptation mechanisms in an auditory oddball paradigm.

Neuropharmacology November 20, 2017 Christopher Timmermann, Meg J. Spriggs, Mendel Kaelen et al. 83 citations

Under the predictive coding framework, perceptual learning and inference are dependent on the interaction between top-down predictions and bottom-up sensory signals both between and within regions in a network. However, how such feedback and feedforward connections are modulated in the state induced by lysergic acid diethylamide (LSD) is poorly understood. In this study, an auditory oddball...

DOI: 10.1016/j.neuropharm.2017.10.039 (opens in new tab) LSD LSD Neuroscience brain Neural adaptation Brain network dynamics +2